Pozen Inc. v. Par Pharmaceutical, Inc., No. 11-1584 (Fed. Cir. Sept. 28, 2012)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

INTRODUCTION Par Pharmaceutical, Inc. (“Par”), Alphapharm Pty Ltd. (“Alphapharm”), and Dr. Reddy’s Laboratories, Inc. (“DRL”) (collectively “Appellants”) appeal from the final judgment of the United States District Court for the Eastern District of Texas. Following a bench trial, the POZEN INC v. PAR PHARMA 3 district court determined that the asserted claims of U.S. Patent No. 6,060,499 (filed Sept. 11, 1998) (the “’499 patent”), U.S. Patent No. 6,586,458 (filed Apr. 27, 2000) (the “’458 patent”), and U.S. Patent No. 7,332,183 (filed Dec.